Sovran Advisors LLC Makes New $472,000 Investment in DaVita Inc. $DVA

Key Points

• Sovran Advisors LLC has made a new investment of approximately $472,000 in DaVita Inc., purchasing 3,282 shares in the second quarter.
• DaVita reported earnings of $2.95 EPS for the most recent quarter, exceeding analysts' expectations of $2.70, with a revenue increase of 6.1% year-over-year.
• Analysts have varied ratings for DaVita, with a consensus "Reduce" rating and an average price target of $158.00 following several price adjustments from major firms.

Sovran Advisors LLC bought a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,282 shares of the company's stock, valued at approximately $472,000.

A number of other large investors have also made changes to their positions in DVA. UMB Bank n.a. boosted its holdings in DaVita by 65.5% in the first quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $29,000 after purchasing an additional 76 shares during the last quarter. Copia Wealth Management acquired a new stake in shares of DaVita during the 4th quarter worth approximately $30,000. National Pension Service increased its holdings in DaVita by 74.3% in the 1st quarter. National Pension Service now owns 197 shares of the company's stock valued at $30,000 after purchasing an additional 84 shares during the last quarter. Y.D. More Investments Ltd acquired a new position in shares of DaVita in the first quarter worth $35,000. Finally, NewEdge Advisors LLC grew its stake in shares of DaVita by 20.8% during the first quarter. NewEdge Advisors LLC now owns 511 shares of the company's stock worth $78,000 after purchasing an additional 88 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Stock Down 0.2%

DVA stock opened at $129.94 on Friday. The company's 50 day simple moving average is $137.15 and its 200-day simple moving average is $141.01. DaVita Inc. has a 52-week low of $126.07 and a 52-week high of $179.60. The firm has a market capitalization of $9.29 billion, a P/E ratio of 12.78, a P/E/G ratio of 0.93 and a beta of 1.13. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.39 and a quick ratio of 1.34.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, beating analysts' consensus estimates of $2.70 by $0.25. The firm had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The firm's revenue was up 6.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.00 earnings per share. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, equities research analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

Insider Activity

In other news, insider James O. Hearty sold 2,351 shares of the company's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the sale, the insider owned 26,038 shares of the company's stock, valued at approximately $3,905,700. This represents a 8.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.50% of the company's stock.

Wall Street Analysts Forecast Growth

DVA has been the subject of a number of research reports. Barclays reduced their target price on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a report on Thursday, August 7th. Bank of America decreased their price target on shares of DaVita from $145.00 to $140.00 and set an "underperform" rating on the stock in a report on Wednesday, September 10th. Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Finally, Truist Financial set a $148.00 price target on shares of DaVita in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, DaVita has a consensus rating of "Reduce" and an average price target of $158.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.